z-logo
Premium
Intravenous Immunoglobulin G Modulates Peripheral Blood T h17 and F oxp3 + Regulatory T Cells in Pregnant Women with Recurrent Pregnancy Loss
Author(s) -
Kim Dong Jae,
Lee Sung Ki,
Kim Jee Yun,
Na Baeg Ju,
Hur Sung Eun,
Lee Millina,
KwakKim Joanne
Publication year - 2014
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12208
Subject(s) - foxp3 , medicine , pregnancy , immune system , antibody , population , immunology , flow cytometry , t cell , andrology , endocrinology , biology , genetics , environmental health
Problem T h17 cells and F oxp3 + regulatory T ( T reg) cells have been proposed as new risk factors for recurrent pregnancy loss ( RPL ). Intravenous immunoglobulin G ( IVIG ) was reported to modulate various immune cells. In this study, we investigated the effect of IVIG on the levels of T h17 and T reg cells and pregnancy outcome in women with RPL . Method of study Thirty‐seven pregnant women with RPL were enrolled in this study. All had cellular immune abnormality in preconceptional evaluation. Blood was drawn on the day of IVIG treatment and 1 week later from the study subjects during early pregnancy. The proportions of IL ‐17 + and F oxp3 + T cells were analyzed using flow cytometry. Results Study population was divided into four groups ( Q 1– Q 4) based on ascending order of the levels of T h17 and F oxp3 + T cells. IVIG down‐regulated T h17 cells in the highest quartile, Q 4 ( P  =   0.001), and up‐regulated CD 4 +   F oxp3 + T cells in Q 1 and Q 2 ( P  =   0.025 and 0.029, respectively). In addition, T h17/ CD 4 +   F oxp3 + T cell ratio decreased in Q 4 ( P  =   0.040). We also found a positive trend between successful pregnancy outcome and CD 8 +   IL ‐17 + T cells before IVIG treatment ( P  =   0.05). Conclusion Intravenous immunoglobulin G treatment modulated imbalance of T h17 and F oxp3 + T reg cells in pregnant RPL women with cellular immune abnormality.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here